Previous Close | 3,783.00 |
Open | 3,771.00 |
Bid | 3,782.00 x 0 |
Ask | 3,785.00 x 0 |
Day's Range | 3,771.00 - 3,820.00 |
52 Week Range | 3,258.00 - 4,490.00 |
Volume | |
Avg. Volume | 2,642,248 |
Market Cap | 6.222T |
Beta (5Y Monthly) | 0.64 |
PE Ratio (TTM) | 16.00 |
EPS (TTM) | 236.44 |
Earnings Date | Oct 24, 2022 |
Forward Dividend & Yield | 76.00 (2.01%) |
Ex-Dividend Date | Dec 29, 2022 |
1y Target Est | 4,555.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for 4519.T
TOKYO, October 14, 2021--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced new longer-term efficacy and safety data for Enspryng® [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. The data show Enspryng has a favourable benefit:risk profile and is effective in reducing relapses over four years of treatment in people with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spe